[Potential utility of optic aggregometry for identification of patients with coronary heart disease resistant to acetylsalicylic acid].
We estimated potential of optic aggregometry for the identification of patients with coronary heart disease in 271 patients with coronary heart disease (CHD) and 230 ones with FC 2-3 angina of effort. Duration of the study was 24 months. Platelet aggregation in patients given anti-aggregation therapy with acetylsalicylic acid (ASA) was assessed with a Biola laser aggregometer (Russia) from changes in transmissivity in the presence of aggregation agonists. Optic aggregometry permitted to distinguish the forms of CHD producing increased risk of atherothrombotic complications in patients with enhanced platelet functional activity resistant to ASA. The prevalence of ACA resistance was estimated at 10% and did not depend on the form of CHD. It was 11.3 and 9.95% in patients with stable angina and acute coronary syndrome respectively. Resistance to ACA was an independent predictor of atherothrombotic complications in patients with different forms of CHD (OR = 8.25; 95% CI 5.77-11.82; p = 0.05).